Prescription drugs, medical devices boost J&J in Q4




Johnson’s brand moisturizing oil, left, and soap, right, by Johnson & Johnson, sit together, Wednesday, Feb. 24, 2021, in Walpole, Mass. Johnson & Johnson (JNJ) on Tuesday, Jan. 25, 2022, reported fourth-quarter profit of $4.74 billion, or $1.77. Adjusted for one-time charges, per-share earnings were $2.13, a penny better than expected on Wall Street, according to analysts surveyed by Zacks Investment Research. (AP Photo/Steven Senne)

Growing prescription drug and medical device sales nudged Johnson & Johnson past fourth-quarter earnings expectations, and the health care giant’s COVID-19 vaccine gained momentum as well.

J&J’s one-shot vaccine rang up $1.62 billion in sales in the last quarter of 2021, or more than double what it had recorded before the quarter, as drugstores and clinics started doling out booster shots.

The vaccine debuted last year and wound up bringing in $2.38 billion, or slightly less than what company leaders have said they expected. J&J said Tuesday that it forecasts vaccine sales of $3 billion to $3.5 billion this year too, as countries continue to fight variants of the coronavirus.

Much of J&J’s vaccine sales came from outside the United States, where regulators said last month that most Americans should receive vaccines from Pfizer or Moderna instead of J&J’s version due to a rare blood clotting problem tied to the shot.

More than 16 million people in the U.S. have become fully vaccinated with the J&J shot, according to the Centers for Disease Control and Prevention. That compares to about 194 million who have used either the Pfizer or Moderna vaccines, which require two doses.

J&J has said it doesn’t intend to profit from the vaccine.

Aside from growing vaccine sales, Johnson & Johnson also saw sales of its blood cancer treatment Darzalex jump 31% to about $1.65 billion.

Total sales from the company’s largest business, pharmaceuticals, jumped more than 16% to $14.29 billion in the quarter. Medical device sales also grew 4% to about $6.9 billion, even though the segment was still hurt by the ongoing pandemic, which has forced patients and hospitals to postpone surgeries and other care.

Johnson & Johnson said in November it will focus on those two segments by splitting off its consumer health business, which sells Band Aids and beauty products, into a separate, publicly traded company.

(Ad)

There aren’t many days left on the calendar… and yet the global semiconductor market grew to $466.2 billion – in spite of the pandemic.

Better still, the chip shortage has created huge opportunities for recurring success.

These four tech companies are well-positioned to take advantage of this rapidly growing demand.

J&J has said it expects that separation to take place over the next couple years.

That segment brought in $3.66 billion in sales during the quarter.

Overall, the world’s biggest maker of health care products earned $4.74 billion in the fourth quarter, while sales grew 10% to $24.8 billion.

Research and development expenses also jumped 17% to $4.7 billion in the quarter.

Adjusted earnings totaled $2.13 per share, or a penny better than expected. Wall Street had expected revenue of $25.28 billion, according to FactSet.

In the full year, Johnson & Johnson earned $20.88 billion — a 42% increase from 2020 — as the company had more than a dozen prescription drugs top $1 billion in sales.

J&J also debuted a strong 2022 forecast of per-share earnings between $10.40 and $10.60. That’s better than the $10.35 Wall Street had been projecting.

Shares of New Brunswick, New Jersey-based Johnson & Johnson, which is a component of the Dow Jones Industrial Average, climbed 1.7% to $165.70 in late morning trading Tuesday. The Dow and other broader indexes were down 1% or more.

___

Follow Tom Murphy on Twitter: https://twitter.com/thpmurphy

7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead

The biotechnology (biotech) sector was one of the best performing sectors in 2020. Many companies saw their stock prices rise as the race was on for a Covid-19 vaccine.

However, many of these companies were pre-revenue companies. Or they were companies that only had one or two in-market products or therapies. And as the calendar turned to 2021, investors took notice. And what went up quickly went down. And in the case of the biotech sector, it came down hard.

One way to tell is to look at biotech ETFs. One of the most popular ETFs, the VanEck Vectors Biotech ETF (NYSEARCA:BBH) is down more than 15%. So you can imagine what it’s been like for many individual biotech stocks. If you’re a buy-and-hold investor, you’re licking some wounds right about now.

But investors who knew what companies to buy have done well. And many of those names will continue to lead the biotech sector in 2022. In this special presentation, we give investors seven biotech stocks that represent different aspects of this diverse sector. We’re confident there’s something for investors of all risk tolerances.

View the “7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead”.

Companies Mentioned in This Article

Compare These Stocks  Add These Stocks to My Watchlist 





Source link



Leave a Reply

Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Chat
Loading the chat ...